Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials.

[1]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[2]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[3]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[4]  R. Califf,et al.  Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. , 1988, Annals of internal medicine.

[5]  R. Conroy,et al.  Risk factors and in-hospital course of first episode of myocardial infarction or acute coronary insufficiency in women. , 1988, Journal of the American College of Cardiology.

[6]  K. Lee,et al.  Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. , 1988, Circulation.

[7]  R. Califf,et al.  Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. , 1988, Circulation.

[8]  E. Topol,et al.  A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. , 1988, The New England journal of medicine.

[9]  R. Califf,et al.  Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. , 1988, The American journal of cardiology.

[10]  H. Gold,et al.  Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. , 1988, Circulation.

[11]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[12]  G. Larsen,et al.  Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. , 1988, Blood.

[13]  R. Califf,et al.  Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. , 1987, Journal of the American College of Cardiology.

[14]  B. Chaitman,et al.  The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. , 1987, Journal of the American College of Cardiology.

[15]  E. Topol.  Advances in Thrombolytic Therapy for Acute Myocardial Infarction , 1987, Journal of clinical pharmacology.

[16]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[17]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[18]  D. Collen,et al.  Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. , 1987, The American journal of cardiology.

[19]  R M Whitlock,et al.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. , 1987, Circulation.

[20]  E. Bolson,et al.  Usefulness of recanalization to luminal diameter of 0.6 millimeter or more with intracoronary streptokinase during acute myocardial infarction in predicting "normal" perfusion status, continued arterial patency and survival at one year. , 1987, The American journal of cardiology.

[21]  R. Balcon,et al.  What proportion of patients with myocardial infarction are suitable for thrombolysis? , 1987, British heart journal.

[22]  P. Shah,et al.  Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. , 1987, The American journal of cardiology.

[23]  J. Hochman,et al.  Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. , 1987, Circulation.

[24]  P. Brugada,et al.  Ventricular arrhythmias initiated by programmed stimulation in four groups of patients with healed myocardial infarction. , 1986, Journal of the American College of Cardiology.

[25]  F. Werf,et al.  Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. , 1986, American heart journal.

[26]  M. Verstraete,et al.  Synergism of thrombolytic agents in vivo. , 1986, Circulation.

[27]  H. Hod,et al.  Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. , 1986, Circulation.

[28]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[29]  S. Strickland,et al.  Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. , 1986, Biochemistry.

[30]  G. Hartzler.  Percutaneous transluminal coronary angioplasty: view of a single relatively high frequency operator. , 1986, The American journal of cardiology.

[31]  J. Douglas,et al.  Percutaneous coronary angioplasty: influence of operator experience on results. , 1986, The American journal of cardiology.

[32]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[33]  J L Ritchie,et al.  The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. , 1985, The New England journal of medicine.

[34]  S. M. Collins,et al.  Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. , 1984, Circulation.

[35]  J L Ritchie,et al.  Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. , 1983, The New England journal of medicine.

[36]  J. Fleiss,et al.  Risk stratification and survival after myocardial infarction. , 1983, The New England journal of medicine.

[37]  R. Gabriel.  IgA DEFICIENCY, HYPERTENSION, AND MULTICYSTIC RENAL DISEASE , 1976, The Lancet.

[38]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .